On the introduction of a trifluoromethyl substituent in the epothilone setting: Chemical issues related to ring forming olefin metathesis and earliest biological findings

Organic Letters

Volumn 4, Issue 23, 2002, Pages 4081-4084

  Rivkin, Alexey ^a   Biswas, Kaustav ^a   Chou, Ting Chao ^a   Danishefsky, Samuel J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKENE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ARTICLE; CELL CULTURE; CELL DIVISION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; SYNTHESIS;

ALKENES; CELL DIVISION; HUMANS; INDICATORS AND REAGENTS; MOLECULAR STRUCTURE; TUMOR CELLS, CULTURED;

EID: 0037078811     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol0268283     Document Type: Article

References (25)

1. For extensive reviews in this field see: (a) Harris, C. R.; Danishefsky, S. J. J. Org. Chem. 1999, 64, 8434.
2. (b) Nicolaou, K. C.; Roschangar, F.; Vourloumis, D. Angew. Chem., Int. Ed. 1998, 37, 2015.
3. Chou, T. C.; O'Connor, O. A.; Tong, W. P.; Guan, Y.; Zhang, Z.-G.; Stachel, S. J.; Lee, C.; Danishefsky, S. J. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 8113.
4. For more information about clinical trials of dEpoB. visit: www.kosan.com.
5. (a) Florsheimer, A.; Altmann, K. H. Expert Opin. Ther. Patents 2001, 11, 951.
6. (b) Chou, T. C.; Zhang, X. G.; Harris, C. R.; Kuduk, S. D.; Balog, A.; Savin, K. A.; Bertino, J. R.; Danishefky, S. J. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 15798.
7. (c) Chou, T. C.; Zhang, X. G.; Balog, A.; Su, D.; Meng, D. F.; Savin, K.; Bertino, J. R.; Danishefsky, S. J. Proc. Natl. Acad Sci. U.S.A. 1998, 95, 9642.
8. (a) Ojima, I.; Inoue, T.; Chakravarty, S. J. Fluorine Chem. 1999, 97, 3.
9. (b) Newman, R. A.; Yang, J.; Finlay, M. R. V.; Cabral, F.; Vourloumis, D.; Stephens, L. C.; Troncoso, P.; Wu, X.; Logothetis, C. J.; Nicolaou, K. C.; Navone, N. M. Cancer Chemother. Pharmacol. 2001, 48, 319.
10. (a) Biswas, K.; Lin, H.; Njardarson, J. T.; Chappell, M. D.; Chou, T. C.; Guan, Y.; Tong, W. P.; He, L.; Horwitz, S. B.; Danishefsky, S. J. J. Am. Chem. Soc. 2002, 124, 9825.
11. (b) Rivkin, A.; Njardarson, J. T.; Biswas, K.; Chou, T. C.; Danishefsky, S. J. J. Org. Chem. 2002, 67, 7737.
12. Chappell, M. D.; Stachel, S. J.; Lee, C. B.; Danishefsky, S. J. Org. Lett. 2000, 2, 1633.
13. Prié, G.; Thibonnet, J.; Abarbri, M.; Duchêne, A.; Parrain, J. Synlett 1998, 839.
14. Reviews: (a) Grubbs, R. H.; Miller, S. J.; Fu, G. C. Acc. Chem. Res. 1995, 28, 446.
15. (b) Trnka, T. M.; Grubbs, R. H. Acc. Chem. Res. 2001, 34, 18.
16. (c) Alkene Metathesis in Organic Chemistry; Fürstner, A., Ed.; Springer: Berlin, Germany, 1998.
17. (d) Fürstner, A. Angew. Chem., Int. Ed. 2000, 39, 3012.
18. (e) Schrock, R. R. Top. Organomet. Chem. 1998, 1, 1.
19. 3-substituted diene did not react at all.
20. (a) Keck, G. E.; Yates, J. B. J. Am. Chem. Soc. 1982, 104, 5829.
21. (b) Review: Curran, D. P. Synthesis 1988, Part 1, p 417; Part 2, p 489.
22. (b) Review: Curran, D. P. Synthesis 1988, Part 1, p 417; Part 2, p 489.
23. Compound 23 ([17]ddEpoB) was prepared in a fashion similar to compound 19 as described in ref 6b.
24. Exposure of epothilones 19 and 23 to nude mouse and human plasma led to degradation of 23 within 30 min, while epothilone 19 remained mostly intact (see ref 2 for details) of this type of measurement. Specifics for 19 and 23 will be reported in due course.
25. VBL100 cell line overexpresses P-glycoprotein and displays a multidrug resistance phenotype to MDR-associated oncolytics.